Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
J.F.R. Robertson(University of Nottingham), Matthew J. Ellis(Washington University in St. Louis), Justin P.O. Lindemann(University Hospital Ostrava), David Feltl(University Hospital Ostrava), Euan Macpherson(University Hospital Ostrava), Antonio Llombart‐Cussac(Universidad Cardenal Herrera CEU), John Dewar(University Hospital Ostrava), Janusz Rolski(Fundación Instituto Valenciano de Oncología)
Cited by 312
Related Papers
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k